Streetwise Reports' Article Archives — May 2013 back to current month (14)
Diagnostics and Stem Cells Power Productive Portfolios: Kevin DeGeeter (05/30/2013)
New medical tests can be moneymakers for small- and mid-cap companies: They save insurers the pain of paying more to treat maladies and save patients from unnecessary treatments. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Director Kevin DeGeeter of Ladenburg, Thalmann & Co. makes his case for diagnostics companies with compelling ideas in the realms of cancer, cardiovascular and surgical testing. He also has one interesting stem cell idea to share.
New Perspectives and Seven Biotechs for a Diversified Portfolio: Ori Hershkovitz (05/30/2013)
Sometimes speaking with investors who work half a world away is just what's needed to get a new angle and hear new names. That was the case when we talked with Ori Hershkovitz, managing partner of the Tel Aviv-based Sphera Global Healthcare Fund. His interest in global markets, following the news flow on his holdings and scouring the earth for new ideas, means Hershkovitz both keeps crazy hours and finds unique prospects. In this interview with The Life Sciences Report, Hershkovitz talks about his favorite names in the biotech space and lays out his growth theory in each case.
Investing in Cancer Research Is Worth the Risk: Echo He (05/23/2013)
If investigators could find a way to make breast cancer survivors truly cancer free, and if a diagnosis of pancreatic cancer were less dire, investors could reap windfalls while patients and their families rejoice. In this interview with The Life Sciences Report, Maxim Group Senior Equity Analyst Echo He brings two important names to the table and explains why she believes the potential upside is worth the risk.
Is the Patent Cliff a Lethal Blow to Big Pharma? (05/23/2013)
"It's a certainty that big phama is going to be keeping close tabs on smaller companies that have promising drugs in phase 2 or 3 trials. Those are certain to be acquired at an accelerating rate, as their larger brethren seek to restock their R&D shelves in the most cost-effective manner."
Biotechnology ETF Investing 101 (05/20/2013)
"The sector maintained its strong performance in 2013 as generic competition is forcing many Pharma companies to engage in merger and acquisition deals."
Two Biotech Ideas You May Have Missed: William Gregozeski (05/16/2013)
Adventurous investors have long sought out micro-cap stocks, attracted by the profit potential of starting on the bottom floor and rocketing toward blue sky. Biotechnology can add even more power to the upside possibilities of micro caps, especially now that pharma is starved for new products and will pay well for solid ideas. Managing partner William Gregozeski of Mont Blanc Capital Management has focused on very small, unnoticed stocks for most of his career and has pegged two undiscovered biotechs that could break out to big-time valuations. In this interview with The Life Sciences Report, Gregozeski elaborates on the stories behind these two investment opportunities.
Position Yourself for Big Returns in the Stem Cell Space: Jason Kolbert (05/10/2013)
Stem cell companies have languished long enough in micro-cap territory. The industry is now approaching highly visible phase 2 and phase 3 catalysts that will produce results never before seen in medicine. Managing Director and Senior Biotechnology Analyst Jason Kolbert of the Maxim Group has staked out a select group of nascent cell therapy companies positioned to reap huge gains for investors willing to diversify. In this interview with The Life Sciences Report, Kolbert reflects on the regenerative medicine space following the recent RegenMed Investor Day conference, and makes an enthusiastic case for his very best ideas.
Takeaway for Biotech Investors: Keep Targeted Cancer Immunotherapies in Mind (05/10/2013)
"Increasingly, the great new medical technologies aren't coming from the pharmaceutical behemoths, but from scrappy little biotech upstarts. In few instances is this truer than in the field of cancer immunotherapy."
Six Superstars for Your Biotech Portfolio: John McCamant (05/09/2013)
We are in the "golden age," of biotech, and Medical Technology Stock Letter Editor John McCamant has innovative ideas on how to glean profits from the renaissance. Investors should be looking at companies with excellent management and platform technologies that offer multiple opportunities for success. McCamant names his favorites in this interview with The Life Sciences Report, including one company with a radical therapy that harkens back to the days before the reign of hand sanitizer.
Case in Point: How Following this 5-Step Biotech Investing Strategy Can Double Your Money (05/07/2013)
"This strategy can avoid some of the biotech sector's biggest risks, while giving you access to the high growth and high returns. And it still gives us the chance to find double-your-money stocks—the chief objective of the Five Tech-Wealth-Investing Rules."
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential (05/02/2013)
In January 2013, The Life Sciences Report debuted its biotech Watchlist, which outlined ideas for investors keyed to catalysts in the drug development process that typically move biotechnology stocks. All stocks are affected by catalysts, but nowhere do they provide more leverage (or deleverage) than in biotech. We predicted the new year would present legitimate prospects for portfolio growth. So far, that has been the case. Although the party has given way to some fatigue, the punch bowl is still on the table and the biotech upswing continues.
The Approval Process in Action (05/01/2013)
What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.
The Approval Process in Action (05/01/2013)
What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.
The Approval Process in Action (05/01/2013)
What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
